Literature DB >> 15183079

Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawal.

María A Sevilla1, Felipe Voces, Rosalía Carrón, Estela I Guerrero, Noelia Ardanaz, Luis San Román, Miguel A Arévalo, María J Montero.   

Abstract

Our objective was to examine the effect of chronic treatment with amlodipine on blood pressure, left ventricular hypertrophy, and fibrosis in spontaneously hypertensive rats and the persistence of such an effect after drug withdrawal. We investigated the effects of treatment with 2, 8 and 20 mg/kg/day of amlodipine given orally for six months and at three months after drug withdrawal. Systolic blood pressure was measured using the tail-cuff method. At the end of the study period, the heart was excised, the left ventricle was isolated, and the left ventricle weight/body weight ratio was calculated as a left ventricular hypertrophy index. Fibrosis, expressed as collagen volume fraction, was evaluated using an automated image-analysis system on sections stained with Sirius red. Age-matched untreated Wistar-Kyoto and SHR were used as normotensive and hypertensive controls, respectively. Systolic blood pressure was reduced in the treated SHR in a dose-dependent way and after amlodipine withdrawal it increased progressively, without reaching the values of the hypertensive controls. Cardiac hypertrophy was reduced by 8 and 20 mg/kg/day amlodipine, but when treatment was withdrawn only the group treated with 8 mg/kg/day maintained significant differences versus the hypertensive controls. All three doses of amlodipine reduced cardiac fibrosis and this regression persisted with the two highest doses after three months without treatment. We concluded that antihypertensive treatment with amlodipine is accompanied by a reduction in left ventricular hypertrophy and regression in collagen deposition. Treatment was more effective in preventing fibrosis than in preventing ventricular hypertrophy after drug withdrawal. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183079     DOI: 10.1016/j.lfs.2004.04.004

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Chronic treatment with pravastatin prevents early cardiovascular changes in spontaneously hypertensive rats.

Authors:  M Kassan; M J Montero; M A Sevilla
Journal:  Br J Pharmacol       Date:  2009-07-23       Impact factor: 8.739

2.  The Effects of Velvet Antler of Deer on Cardiac Functions of Rats with Heart Failure following Myocardial Infarction.

Authors:  Ming-Jing Shao; Shuo-Ren Wang; Ming-Jing Zhao; Xi-Ling Lv; Hao Xu; Lin Li; Huan Gu; Jiu-Liang Zhang; Ge Li; Xiang-Ning Cui; Li Huang
Journal:  Evid Based Complement Alternat Med       Date:  2012-04-24       Impact factor: 2.629

3.  The right choice of antihypertensives protects primary human hepatocytes from ethanol- and recombinant human TGF-β1-induced cellular damage.

Authors:  Sabrina Ehnert; Teresa Lukoschek; Anastasia Bachmann; Juan J Martínez Sánchez; Georg Damm; Natascha C Nussler; Stefan Pscherer; Ulrich Stöckle; Steven Dooley; Sebastian Mueller; Andreas K Nussler
Journal:  Hepat Med       Date:  2013-03-22

Review 4.  Conduction abnormalities and ventricular arrhythmogenesis: The roles of sodium channels and gap junctions.

Authors:  Gary Tse; Jie Ming Yeo
Journal:  Int J Cardiol Heart Vasc       Date:  2015-12-07

5.  Relationship Between the Gastrointestinal Side Effects of an Anti-Hypertensive Medication and Changes in the Serum Lipid Metabolome.

Authors:  Yoomin Ahn; Myung Hee Nam; Eungbin Kim
Journal:  Nutrients       Date:  2020-01-13       Impact factor: 5.717

6.  Angiotensin-converting enzyme inhibitors increase anti-fibrotic biomarkers in African Americans with left ventricular hypertrophy.

Authors:  Cesar A Romero; Shobi Mathew; Benjamin Wasinski; Brian Reed; Aaron Brody; Rachelle Dawood; Michael J Twiner; Candace D McNaughton; Rafael Fridman; John M Flack; Oscar A Carretero; Phillip D Levy
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-03-10       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.